RxDoctor Payments DataLook up a doctor →

Mir Basir, DO

Interventional Cardiology · Detroit, MINPI 1326369695

Payments from drug & device makers

$770,693in general payments, 2019–2025

Across 410 payments — averaging $1879.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$232K
  • ZOLL Circulation Inc$208K
  • Chiesi USA, Inc.$164K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$67K
  • Saranas, Inc.$61K
  • Boston Scientific$20K
  • plus $19K from 14 others
$220in research payments, 2019–2025

Across 1 payment — averaging $220.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Circulation Inc$220

What the payments were for

  • Consulting fees$118,88527%
  • Speaking & faculty fees$280,58563%
  • Travel & lodging$34,0108%
  • Food & beverage$8,5632%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$770,693 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$90,452
Medicare patients
158
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$113,767
EliquisApixaban48$56,840
EntrestoSacubitril/Valsartan22$27,727
FarxigaDapagliflozin Propanediol24$24,747
Repatha SureclickEvolocumab24$18,019
BrilintaTicagrelor12$8,605
Praluent PenAlirocumab11$4,817
Atorvastatin Calcium158$2,227
Metoprolol Succinate104$1,482
Carvedilol80$1,140
Losartan Potassium79$1,106
ClopidogrelClopidogrel Bisulfate66$1,073
Spironolactone93$979
Bumetanide16$868
Isosorbide Mononitrate ErIsosorbide Mononitrate33$710

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →